Light at the end of the tunnel? by Machado‐aranda, D.a. & Raghavendran, K.
 
This is the author manuscript accepted for publication and has undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/jlb.10513. 
This article is protected by copyright. All rights reserved. 
Light at the end of the tunnel? 
D.A. Machado-Aranda1, K. Raghavendran1 
1-Division of Acute Care surgery, Department of Surgery 
University of Michigan 
 
Circadian rhythms respond primarily to darkness and light. Their importance in 
critical illness, though recognized for some time, remains poorly understood. In this 
edition of JLB, Griepentrog et al report that using a clinically relevant model of 
Klebsiella pneumoniae, blue spectrum light enhanced immune competence.1 
Klebsiella pneumoniae (KP) account for a significant proportion of community and 
hospital acquired pneumonia. They are particularly virulent as they cause significant 
alveolar necrosis and have the potential to cause septicemia.2 Additionally, 
Carbapenam-resistant KP is associated with a mortality of 45-60%. Due to the 
alarming increase in Carbapenam-resistant Enterobacteriaceae (CRE), of which KP 
comprises the majority of infections, the Centers for Disease Control (CDC) have 
designated these bacteria as an urgent threat to public health.3 Therefore, new 
therapeutic strategies are urgently needed.  
Blue light is part of the spectral light that primarily stimulates the proteins involved in 
the circadian rhythm, located within the supra-chaismatal nucleus.  These set of 
studies complement previous studies from the same authors that show that blue light 
reduced inflammation and organ injury in a sterile model of ischemia-reperfusion 
injury.4 The authors first demonstrate that blue light reduces the heart rate as well as 
heart rate variability suggesting a predominant parasympathetic stimulation. Using a 
lethal model of KP that is introduced through intra-tracheal inoculation, the authors 
then show that blue light selectively improves survival and bacterial clearance from 
all the organs including the lung and cause a reduction in bacteremia. 
Correspondingly, blue light is accompanied by reduced alveolar neutrophil influx and 
reduction in lung inflammation. Blue light failed to show similar results in transgenic 
mice (Vsx2-/-) with absence of the optic nerve and using α-bungaro toxin, a 
competitive inhibitor of nicotinic cholinergic receptors, the authors demonstrated that 
blue light functioned through an optic-cholinergic pathway. Finally, the authors note 
that circadian clock protein Rev-Erb-α is primarily involved in these processes by 
using biochemical activation with agonist SR9009 resulting in enhanced bacterial 
elimination in-vivo and improved macrophage phagocytic activity in in-vitro studies. A 
subsequent study using Knock in or knock out animals with Rev-Erb-α would be 
complementary to this study as the synthetic agonists have been known to have 
multiple off target effects.5  
It is interesting to note that Rev-Erb-α, a portion of the feedback loop regulating the 
CLOCK proteins involved in the circadian regulation also take part in regulation of 
metabolic processes. Rev-Erb-α has been found to modulate lipid, glucose, bile acid 
metabolism, adipogenesis, and generation of acute inflammatory response6. 
Additionally, Rev-Erb-α has been shown to modulate metabolism of triglyceride-rich 
lipoproteins that are associated with increased risk of cardiovascular disease through 
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modulation of inflammation in atherosclerosis.7 Several studies have reported on 
novel natural 8and synthetic ligands for Rev-Erb-α.9 Modulation of these ligands may 
represent a promising target for the treatment of metabolic abnormalities resulting 
from chronic aberrant circadian rhythms.   
However, history teaches us that regulation of inflammation could be a double edged 
sword. A robust inflammatory response with appropriate phenotypic characterization 
of alveolar macrophages is needed for bacterial clearance. Moreover, there are 
conflicting sets of data regarding Rev-Erb-α. In human macrophages, Rev-Erb-α has 
been shown to repress the induction of toll-like receptor (TLR)-4,10 the primary TLR 
involved with gram-negative bacterial pathogenesis. Finally, as the authors have 
acknowledged, studies in predominantly nocturnal animals such as mice may not 
have any human translational significance. Clinical studies in critically ill patients with 
blue light augmentation are eagerly awaited and it remains to be seen if blue light 
represents the light at the end of the tunnel or is just a train coming over from the 
other end. 
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